Rznomics Secures Over ₩60.9 Billion in Funding to Transform RNA-Based Therapies in Oncology and Beyond

Rznomics, a trailblazer in the biopharmaceutical arena, is proud to announce its latest funding milestone, having raised 1,300,000,000 in its most recent financing round. This investment builds on the company’s impressive track record of raising approximately 60.9 billion through previous Series A, B, and C rounds, as well as securing an additional 8 billion in government research funding. Focused on developing safe and effective treatments for oncology, degenerative, and genetic diseases, Rznomics leverages its groundbreaking RNA platform technology—specifically its proprietary trans‐splicing ribozyme—to target some of the most challenging medical conditions of our time. The new capital injection is earmarked for advancing its innovative pipeline, which includes RZ-001, an investigational drug for hepatocellular carcinoma (HCC) that received IND approval from the MFDS in 1H 2022 and is currently in clinical trials. In addition to its promising HCC treatment, Rznomics is advancing competitive therapies for glioblastoma multiforme, Alzheimer’s disease, genetic ocular diseases such as retinitis pigmentosa, and exploring novel applications in circular RNA technology. This funding will not only accelerate clinical development and regulatory milestones but will also bolster the company’s collaborations with global industry leaders in co-research, co-development, and licensing. By expanding its research capabilities and strategic partnerships, Rznomics is well positioned to transform the landscape of biopharmaceutical innovation, delivering next-generation therapeutics that address unmet medical needs and improve patient outcomes worldwide.